$NVO news
The latest NVO stock news: headlines, filings, AI summaries and sentiment for $NVO, updated around the clock.
- China Approves Eli Lilly's Oral GLP-1 Weight-Loss Drug Orforglipron
- Hims & Hers Reports Q3 2026 Revenue Growth Amid Strategic Marketing Pullback
- FDA Mandates Safety Warnings for GLP-1 Drugs Over Potential Vision Loss Risk
- FDA Requires Vision Loss Warning Label for GLP-1 Weight-Loss Drugs
- US Markets Recover from Post-Election Slump Amid Positive Clinical Trial Data for Eli Lilly and Johnson & Johnson
- Novonesis Explores Microbiome Supplements to Complement GLP-1 Weight-Loss Treatments
- Amgen Develops Monthly Obesity Drug MariTide to Challenge Weekly Injection Market
- Novo Nordisk Reports Strong Third Quarter Results Driven by Oral Wegovy Growth
- Ginkgo Bioworks Shifts Strategy Toward Autonomous Lab Hardware and Cloud Services
- Ginkgo Bioworks Reaffirms 2026 Cash Burn Guidance and Announces Autonomous Lab Sale to Novo Nordisk
- Novo Nordisk CEO Provides Timeline for CagriSema Obesity Drug Launch
- Lexicon Pharmaceuticals Reports Q3 2026 Financial Results and Clinical Pipeline Updates
- Novo Nordisk Raises Full-Year Guidance Following Strong Q3 Patient Growth and Pipeline Progress
- Novo Nordisk Raises 2026 Outlook Amid Strong Obesity Drug Sales but Declines 2027 Guidance
- Novo Nordisk Reports Q3 2026 Growth Driven by GLP-1 Portfolio and Wegovy Expansion
- Novo Nordisk Reports Strong Q3 Results Driven by Obesity Care Growth
- Premarket Market Analysis: Trump Media, Tesla, and Novo Nordisk Lead Volatility Following Election Results
- Novo Nordisk Raises Annual Outlook Amid Strong Demand for Wegovy and Ozempic
- Novo Nordisk Exceeds Q3 Earnings and Revenue Estimates, Updates 2026 Outlook
- Novo Nordisk Raises Full-Year Outlook Following Strong Wegovy Sales
- Key Corporate Earnings Reports Scheduled Before Wednesday Market Open
- Eli Lilly Shares Surge Toward Record Highs on Strong GLP-1 Drug Demand
- Novo Nordisk Scheduled to Report Third Quarter Earnings Results
- UBS Initiates Coverage on Viking Therapeutics with Buy Rating and $94 Price Target
- Eli Lilly Raises Price Target Amid Strong Third Quarter Earnings and Obesity Drug Growth
- Eli Lilly Reports Strong Q3 Results Driven by Mounjaro and Jardiance Growth
- Eli Lilly Raises Full-Year Revenue Outlook Driven by Strong Weight-Loss Drug Demand
- Eli Lilly Set to Report Third-Quarter Earnings Driven by Obesity and Diabetes Drugs
- Eli Lilly's Retatrutide Demonstrates Superior Weight Loss and A1C Reduction Compared to Ozempic in Phase 3 Trial
- US Judge Denies Novo Nordisk Request to Halt Eli Lilly Weight-Loss Drug Advertisements
- Eli Lilly Announces Quarterly Dividend of $1.73 Per Share
- Bristol Myers Squibb and Novo Nordisk Comparative Revenue Analysis
- Novo Nordisk's CagriSema Shows 25% Weight Loss in Phase 3 Clinical Trial
- Novo Nordisk's CagriSema Achieves Average Weight Loss of 25% in Women
- OpenAI Acquires Orchestra Bio to Enhance Biotech Capabilities
- Novo Nordisk's Experimental Obesity Drug Shows Significant Weight Loss in Women
- Walmart Expands Employee Healthcare Benefits, Covering GLP-1s, Insulin, and Inhalers at No Cost Starting 2027
- Four Healthcare Stocks Worth Owning for Long-Term Growth
- GLP-1 Drugs Are Changing Eating Habits and Impacting Food Industry Revenue
- FDA Extends Review Period for Novo Nordisk's Denecimig Hemophilia Treatment
- Anthropic to Invest $100 Million in Training Program for AI Engineers
- Novo Nordisk Announces Two Major Licensing Deals Worth Nearly $4 Billion
- Eli Lilly and Novo Nordisk Develop Amylin-Based Obesity Drugs as Complement or Alternative to GLP-1s
- Big Pharma Companies Partner with Chinese Biotechs Amid Patent Expirations
- Regeneron and Novo Nordisk Combination Therapy Reduces Muscle Loss in Study
- Viking Therapeutics Shares Rise Over 30% on Encouraging Weight-Loss Drug Trial Results
- Patients Switching to Oral Wegovy Continue Weight Loss in Real-World Study
- Novo Nordisk Licenses Obesity Drug from Hengrui for Up to $2.6 Billion
- Bristol Myers Squibb vs. Novo Nordisk: A Comparative Analysis of Healthcare Stocks for 2026
- Viking Therapeutics Reports Positive VK2735 Maintenance Trial Results but Faces Oral Formulation Challenges